Keryx Biopharmaceuticals (NASDAQ: KERX) is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.
The Company has announced that its upcoming Analyst Day will be webcast live on Thursday, June 21, 2012 at 4:30 pm ET. Scheduled speakers include the following:
- Julia Lewis, M.D. will provide her perspective on the Zerenex (ferric citrate) Phase 3 clinical program and the potential Zerenex product profile.-- Professor of Medicine, Division of Nephrology, Vanderbilt University School of Medicine
- Geoffrey Block, M.D. will discuss the potential for Zerenex in pre-dialysis.-- Director of Research, Denver Nephrology and Associate Clinical Professor in Medicine, University of Colorado Health Sciences Center
- David Goldfarb, M.D. will discuss the potential importance of citrate.-- Chief, Nephrology Division, NY Campus of NY Harbor Health Care Veterans Affairs System and Professor of Medicine & Physiology, NYU School of Medicine.
To access the live audio webcast, please visit the Company's Investor Relations section of their website ( http://investors.keryx.com ). An archived version of the webcast will become available following the conclusion of the live presentation.